^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BG34-200
i
Other names: BG34-200
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Case Western Reserve University
Drug class:
CD11b agonist
Related drugs:
over2years
Carbohydrate ligand engagement with CD11b enhances differentiation of tumor-associated myeloid cells for immunotherapy of solid cancers. (PubMed, J Immunother Cancer)
Our research has advanced the current understanding of the molecular basis of CD11b activation in solid cancers, revealing how it converts the differences in BG34 carbohydrate ligands into immune signaling responses. These findings could pave the way for the development of safe and novel BG34-200-based therapies that modulate myeloid-derived cell functions, thereby enhancing immunotherapy for solid cancers.
Journal
|
ICAM1 (Intercellular adhesion molecule 1) • ITGAM (Integrin, alpha M)
|
BG34-200
almost3years
BG34-200 immunotherapy of advanced melanoma (AACR 2023)
The scientific findings from this study will allow us to develop new technology to apply BG34-200-based immunotherapy to patients with advanced melanoma who have not responded to current standard of care therapies with and without immunotherapy.
Metastases
|
ITGAM (Integrin, alpha M)
|
BG34-200
Share via
